Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04334174 | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster…(BRENTICON-T) | Phase 2 | withdrawn | Apr 6, 2020 | University of Kansas Medical Center | accrual not met | Enrollment / accrual |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell… | Phase 1 | terminated | Mar 15, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | Phase 2 | terminated | Dec 10, 2012 | Dana-Farber Cancer Institute | Slow accrual and futility | Efficacy / futility |
| NCT02077959 | Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple… | Phase 1 | terminated | Mar 4, 2014 | Ohio State University Comprehensive Cancer Center | Pharmaceutical Companies decision | Other (stated, no rule matched) |
| NCT05408026 | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | Phase 1 / Phase 2 | withdrawn | Jun 7, 2022 | Alliance Foundation Trials, LLC. | Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest. | Other (stated, no rule matched) |
| NCT05493618 | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. | Phase 1 / Phase 2 | withdrawn | Aug 9, 2022 | Hackensack Meridian Health | Study Drug Unavailability | Other (stated, no rule matched) |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory…(SLAM) | Phase 1 / Phase 2 | withdrawn | Mar 17, 2015 | Karyopharm Therapeutics Inc | Terminated this trial and added a Lenalidomide arm to KCP-330-017 | Other (stated, no rule matched) |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone…(SCORE) | Phase 2 | withdrawn | Dec 11, 2015 | Karyopharm Therapeutics Inc | not stated | Not stated |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | Phase 2 | terminated | Apr 24, 2013 | BioInvent International AB | Sponsor's decision | Sponsor / business decision |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | Phase 1 / Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell… | Investigator |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT00096460 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent… | Phase 2 / Phase 3 | terminated | Nov 10, 2004 | Medical College of Wisconsin | lower than anticipated accrual | Enrollment / accrual |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Oct 14, 2009 | Mayo Clinic | not stated | Not stated |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in…(ANCHOR) | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction… | Phase 2 | withdrawn | Jan 10, 2020 | Attaya Suvannasankha | lack of funding | Funding |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With… | Phase 3 | terminated | Mar 9, 2016 | Janssen Research & Development, LLC | IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed… | Efficacy / futility |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | Phase 1 | terminated | Mar 4, 2021 | Samus Therapeutics, Inc. | Samus Therapeutics Company Closure | Sponsor / business decision |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | Early Phase 1 | withdrawn | Jul 30, 2021 | Weill Medical College of Cornell University | Funding withdrawn | Funding |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to… | Phase 1 / Phase 2 | terminated | Jun 20, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic… | Phase 1 / Phase 2 | terminated | Aug 15, 2011 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell… | Phase 1 / Phase 2 | terminated | Jun 23, 2020 | Akeso | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop… | Sponsor / business decision |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front… | Phase 2 | withdrawn | Feb 15, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell… | Phase 1 | terminated | Mar 23, 2016 | Ludwig Institute for Cancer Research | FDA placed on partial hold due to additional data | Other (stated, no rule matched) |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | Phase 2 | terminated | Aug 24, 2015 | Rush University Medical Center | poor accrual | Enrollment / accrual |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple…(ProxiMMity-1) | Phase 1 | withdrawn | Aug 10, 2021 | Amgen | Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons. | Safety / toxicity |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed… | Phase 1 | suspended | Feb 9, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to the product development strategy change, without any safety concerns, we (the sponsor of the… | Safety / toxicity |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons | Safety / toxicity |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | Phase 1 | terminated | Dec 14, 2021 | Codiak BioSciences | PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety… | Safety / toxicity |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and… | Phase 1 / Phase 2 | terminated | Dec 20, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or…(ARGO) | Phase 2 | terminated | Feb 5, 2018 | University Hospital Southampton NHS Foundation Trust | Failure to reach pre-specified futility boundary | Efficacy / futility |
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | Phase 1 | terminated | Dec 19, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or…(MT-3724NHL001) | Phase 1 / Phase 2 | terminated | Feb 11, 2015 | Molecular Templates, Inc. | Sponsor decision following clinical hold | Sponsor / business decision |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and… | Phase 2 | terminated | Apr 4, 2018 | Molecular Templates, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03645395 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of… | Phase 2 | terminated | Aug 24, 2018 | Molecular Templates, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04973527 | LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor | Phase 1 | terminated | Jul 22, 2021 | Beijing Boren Hospital | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 3, 2023source: clinicaltrials